Loading
Bexobrutideg is an experimental protein degrader from Nurix Therapeutics in phase 3 trials for chronic lymphocytic leukaemia, aimed at BTK (Bruton tyrosine kinase).
Bexobrutideg (NX-5948) is a protein degrader developed by Nurix Therapeutics. Its target is BTK (Bruton tyrosine kinase) (the sponsor names BTK (Bruton's tyrosine kinase)). The sponsor states: NX-5948 is an oral, CNS-penetrant BTK degrader that removes the BTK protein rather than only inhibiting its activity, which the sponsor states may help overcome kinase-domain and scaffolding-mediated resistance mutations. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07516093 (Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL), in chronic lymphocytic leukaemia. The largest, NCT07516093, plans to enrol 620 participants with primary completion expected 2029-10. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
NX-5948 is an oral, CNS-penetrant BTK degrader that removes the BTK protein rather than only inhibiting its activity, which the sponsor states may help overcome kinase-domain and scaffolding-mediated resistance mutations. Connects to BTK (Bruton tyrosine kinase).
1.Bexobrutideg binds BTK (Bruton tyrosine kinase) with one end and an E3 ubiquitin ligase with the other.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Bexobrutideg" OR ABSTRACT:"Bexobrutideg" OR TITLE:"NX-5948" OR ABSTRACT:"NX-5948") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Bexobrutideg, not a curated reading list.
Shares Chronic lymphocytic leukaemia and the tag pipeline.
Shares Chronic lymphocytic leukaemia and the tag pipeline.
Shares Chronic lymphocytic leukaemia and the tag pipeline.
Shares Chronic lymphocytic leukaemia and the tag pipeline.
Shares Chronic lymphocytic leukaemia and the tag pipeline.
Shares Chronic lymphocytic leukaemia and the tag pipeline.
Shares Chronic lymphocytic leukaemia and the tag pipeline.
Shares Chronic lymphocytic leukaemia and the tag pipeline.